Technology
Extracellular matrix preservation (BioECM) technology.
Imagine in the future: altering one's biology to quickly repair a tear (ACL, shoulder, bicep, etc)
Imagine in the future: eliminating back and joint pain
Imagine in the future: rejuvenating tissues and extending lifespan by restoring function
Imagine in the future: recovering rapidly post-surgery with reduced pain and scarring
Our Breakthrough Approach
As one ages, the body’s ability to repair and remodel decreases, causing what is called a broken healing-loop due to a lack of native functional tissue. Employing innovative science, Skye is discovering and developing breakthrough therapeutics that hack and optimize the repair process that leads to organized advanced healing with minimal scarring, complications, failure, or re-injury.
Our novel approach unravels the code of complex molecules from naturally advanced human biological material, which is isolated and applied to treat a multitude of conditions across a range of surgical and non-surgical specialties, including orthopedics, spine, sports medicine, chronic and complex wounds, plastic surgery, urology, gynecology and general surgery. Targeted therapies under development have the power to help upwards of 50 million patients per year.
Pipeline
Medicines with breakaway potential.
Products
Industry leading unique tissue transplants.
Who we are
Tackling a current $100+ billion healthcare spend, Skye is rapidly advancing multiple future regenerative biological therapies that will target all areas both surgically and non-surgically of the musculoskeletal system, internal tissue structures and areas where there is a high-unmet medical need by leveraging its platform and expertise. One of the goals is that the therapies in development will reduce the historically high cost of treatment in our healthcare system with better patient outcomes. We are dedicated and strive to accelerate to market regenerative solutions that dramatically improve people's lives and longevity. A biotech leader since 2010, Skye has grown to be one of the world's leading independent new age biotechnology companies, has reached hundreds of thousands of patients in the US with existing tissue products and is developing a pipeline of medicines with breakaway potential for decades to come.
